Feb 29 |
Biohaven GAAP EPS of -$1.81 misses by $0.40
|
Feb 29 |
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
|
Feb 28 |
Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
|
Feb 18 |
A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
|
Feb 16 |
RBC Capital starts Biohaven at outperform, cites epilepsy drug
|
Feb 7 |
UBS starts Biohaven at buy, cites diverse pipeline
|
Jan 25 |
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
|
Jan 22 |
Obesity Drugs Lead to Muscle Loss—Pharma Companies Want to Fix That
|
Jan 8 |
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and On...
|
Jan 2 |
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|